Almirall at a glance

Who we are

We are a global pharmaceutical company dedicated to medical dermatology. As a family-owned business, we think in generations and apply this long-term view to our contributions to people with skin conditions, placing patients at the center of our business ambitions.



Headquatered in	Offices around the world	Total employees	Country presence
Barcelona	14	2,027	102

Patients at the core

Number of products

143

Dermatology products

Patients we have helped with our key dermatology products¹

628,181



¹ The total number includes Klisyri® (tirbanibulin), Ilumetri® (tildrakizumab), Wynzora® (calcipotriol/betamethasone) and Seysara (sarecycline) in 2023.

Our therapeutic focus

Immune inflammatory diseases

Atopic dermatitis Psoriasis Hidradenitis suppurativa Alopecia areata Vitiligo

Non-melanoma skin cancer

Actinic keratosis Basal cell carcinoma Cutaneous T-cell lymphoma Squamous cell arcinoma

Rare diseases

Autoimmune bullous diseases Epidermolysis bullosa Palmoplantar pustulosis

What we do

With an R&D pipeline solely focused on medical dermatology, we are at the forefront of science to develop and deliver ground-breaking, differentiated end-to-end products that address patients' needs. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose of improving patients' lives holistically.





Driven by innovation

Investment of Net Sales in R&DCurrent projects in the pipelineCurrent collaborations and partnerships in R&D12.6%1323

Collaborative mindset

Almirall innovation Hub The Hive

A novel scientific research hub located at our R&D centre

ZeClinics (genetics research)

Centrient Pharmaceuticals (sustainable biosynthetic pharmaceutical products)

ADmit Therapeutics (early detection of Alzheimer)

Microomics (DNA sequencing technologies).

Barcelona Supercomputing Center and Nostrum Biodiscovery – ARTIBAND Generative artificial intelligence (AI)

CRG Non-melanoma skin cancer and atopic dermatitis

Isolex IgE-mediated disease therapies

Absci generative AI **Etherna** mRNA-based therapies for serious skin conditions

EpimAb bispecific antibodies

Eloxx pharmaceticals Rare diseases

Novo Nordisk Autoinmune dermatology diseases



Pipeline

Molecule name	Indication	Phase I	Phase II	Phase III	Registration	Geography
Sarecycline	Acne					China
Tirbanibulin	Actinic keratosis (LF)					Europa
Tildrakizumab	Psoriatic arthritis					Europa
Lebrikizumab	Atopic Dermatitis pediatric					Europa
Anti-IL-21 mAb	Inflammatory skin disease		•			Worldwide
Anti-IL-1RAP mAb	Hidradenitis Suppurativa					Worldwide
IL-2muFc*	Inflammatory skin disease					Worldwide
ZKN-013**	Rare dermatology (RDEB/JEB)					Worldwide

*Worldwide ex- Greater China

**EBDR/EBJ: Epidermólisis Bullosa Distrófica Recesiva / Epidermólisis Bullosa Juncional





Our 2030 Sustainability Strategy

Act for impact is a strategic factor in our plan to make a meaningful and lasting difference in society and the environment while upholding its core principles of transparency, responsibility, ethics, and compliance.

GOING BEYOND FOR A GREATER IMPACT



Take bold action on climate through our science-led **Net Zero Emissions Strategy**, delivering our energy decarbonisation, sustainable mobility and sustainable procurement plans.

Promote actions towards water stewardship, circular economy, and nature protection.





Strengthen our commitment to patients through our **Patient Organisations Engagement Plan** with a special focus on our derma patient's wellbeing. Reinforce a **Patient Centric Mindset** across

all Almirall and prioritize the needs of patients, putting them at the core of our decisions.





Further integrate sustainability into the company's strategy and governance, increase our transparency by continuing to report to best-in-class ESG rating agencies and ensure an **ethical culture and mindset**, being **accountable** in all our actions.



People R

Implement a Global Diversity, Equity and Inclusion Plan, enhance our Talent Management to unleash our employees full potential, deploy our corporate holistic Wellbeing Programme and consolidate a Corporate Volunteering Programme.





Deploy our sustainable procurement programme, through an enhanced Supplier Risk Management Process, implementing tools and platforms to support the process, ensuring effective governance and reinforcing sustainability-related aspects in the relationship f with our value chain.



Sustainability & ESG Ratings:













